Global Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2030

Description

List of Tables

The global duchenne muscular dystrophy treatment market is expected to reach USD 8,654,688.51 thousand by 2030 from USD 2,595,090.00 thousand in 2022, growing at a CAGR of 16.8% in the forecast period of 2023 to 2030.

Market Segmentation

Global Duchenne Muscular Dystrophy Treatment Market, By Treatment Type (Molecular-Based Therapies, Steroid Therapy, and Others), Therapy (Exon Skipping Approach, Mutation Suppression, and Dystrophin-Targeted Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Global Duchenne Muscular Dystrophy Treatment Market Dynamics

Driver
Increasing prevalence and impact of Duchenne Muscular Dystrophy (DMD) disease
Restraint
High treatment cost of DMD disorder
Opportunity
Strategic initiatives by key market players

Market Players

Some of the key market players for global duchenne muscular dystrophy treatment market are:

Sarepta Therapeutics, Inc.
Solid Biosciences Inc.
Capricor Therapeutics, Inc.
Dyne Therapeutics
BioMarin
Stealth BioTherapeutics Inc
Avidity Biosciences
ReveraGen
BioPharma, Inc.
TAIHO PHARMACEUTICAL CO., LTD.
Akashi RX
ITALFARMACO S.p.
NS Pharma, Inc.
PTC Therapeutics.
Pfizer Inc.
FibroGen, Inc.
SANTHERA PHARMACEUTICALS
F. Hoffmann-La Roche Ltd

1 INTRODUCTION 45

1.1 OBJECTIVES OF THE STUDY 45
1.2 MARKET DEFINITION 45
1.3 OVERVIEW OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 45
1.4 CURRENCY AND PRICING 47
1.5 LIMITATIONS 47
1.6 MARKETS COVERED 47

2 MARKET SEGMENTATION 49

2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 DBMR TRIPOD DATA VALIDATION MODEL 52
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.6 MULTIVARIATE MODELLING 56
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 56
2.8 MARKET END USER COVERAGE GRID 57
2.9 DBMR MARKET POSITION GRID 58
2.10 VENDOR SHARE ANALYSIS 59
2.11 SECONDARY SOURCES 60
2.12 ASSUMPTIONS 60

3 EXECUTIVE SUMMARY 61

4 PREMIUM INSIGHTS 63

4.1 PESTEL'S MODEL 64
4.2 PORTER'S FIVE FORCES MODEL 65
4.3 PRICING ANALYSIS 65

5 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: REGULATIONS 67

5.1 REGULATIONS IN U.S. 67
5.2 REGULATTIONS IN EUROPE 68
5.3 REGULATTIONS IN AUSTRALIA 68
5.4 REGULATIONS IN SOUTH AFRICA 68
5.5 REGULATIONS IN BRAZIL 69

6 MARKET OVERVIEW 70

6.1 DRIVERS 72
- 6.1.1 INCREASING PREVALENCE AND IMPACT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) DISEASE 72
- 6.1.2 INTRODUCTION OF NOVEL THERAPIES FOR DMD DISORDER 72
- 6.1.3 RISING AWARENESS FOR DMD TREATMENTS 73
- 6.1.4 INCREASE IN THE NUMBER OF CLINICAL TRIALS IS A RECENT TREND 74
6.2 RESTRAINTS 75
- 6.2.1 LIMITED AVAILABILITY OF DMD TREATMENTS DUE TO LACK OF ADVANCE TECHNOLOGY 75
- 6.2.2 HIGH TREATMENT COST OF DMD DISORDER 76
6.3 OPPORTUNITIES 77
- 6.3.1 DEVELOPMENT OF HEALTHCARE INFRASTRUCTURE AND INCREASING INVESTMENT 77
- 6.3.2 RISING PATIENT INCLINATION TOWARDS PERSONALIZED AND EFFECTIVE THERAPIES 77
- 6.3.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 78
- 6.3.4 SUPPORT FROM PATIENT ADVOCACY GROUPS ON THE REGULATORY APPROVAL PROCESS 78
6.4 CHALLENGES 79
- 6.4.1 LACK OF STANDARDIZATION IN DMD DIAGNOSIS 79
- 6.4.2 ETHICAL CONSIDERATIONS RELATED TO PERMANENT ALTERATION OF A PATIENT'S GENETIC CODE 80

7 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE 81

7.1 OVERVIEW 82
7.2 MOLECULAR-BASED THERAPIES 85
- 7.2.1 ANTISENSE OLIGONUCLEOTIDE THERAPY 86
  - 7.2.1.1 EXONDYS 51 86
  - 7.2.1.2 AMONDYS 45 87
  - 7.2.1.3 VYONDYS 53 87
7.3 NONSENSE MUTATION 87
7.4 STEROID THERAPY 88
- 7.4.1 PREDNISONE 88
- 7.4.2 DEFLAZACORT 88
7.5 OTHERS 89

8 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY 90

8.1 OVERVIEW 91
8.2 EXON SKIPPING APPROACH 94
- 8.2.1 MULTI-EXON SKIPPING APPROACH 94
- 8.2.2 SINGLE-EXON SKIPPING APPROACH 95
8.3 MUTATION SUPPRESSION 95
8.4 DYSTROPHIN-TARGETED THERAPIES 96
- 8.4.1 GENE THERAPIES 96
- 8.4.2 CELL THERAPIES 97
  - 8.4.2.1 Gene Editing 97
  - 8.4.2.2 Gene Addition 97

9 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 98

9.1 OVERVIEW 99
9.2 PARENTERAL 102
9.3 ORAL 103
9.4 OTHERS 104

10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER 105

10.1 OVERVIEW 106
10.2 HOSPITALS 109
10.3 SPECIALTY CLINICS 110
10.4 HOMECARE 111
10.5 OTHERS 112

11 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL 113

11.1 OVERVIEW 114
11.2 HOSPITAL PHARMACY 117
11.3 RETAIL PHARMACY 118
11.4 ONLINE PHARMACY 119

12 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION 120

12.1 OVERVIEW 121
12.2 NORTH AMERICA 124
- 12.2.1 U.S. 129
- 12.2.2 CANADA 134
- 12.2.3 MEXICO 139
12.3 EUROPE 145
- 12.3.1 GERMANY 151
- 12.3.2 FRANCE 156
- 12.3.3 U.K. 161
- 12.3.4 ITALY 166
- 12.3.5 SPAIN 171
- 12.3.6 RUSSIA 176
- 12.3.7 TURKEY 181
- 12.3.8 BELGIUM 186
- 12.3.9 NETHERLANDS 191
- 12.3.10 SWITZERLAND 196
- 12.3.11 REST OF EUROPE 201
12.4 ASIA-PACIFIC 202
- 12.4.1 CHINA 207
- 12.4.2 JAPAN 212
- 12.4.3 INDIA 217
- 12.4.4 SOUTH KOREA 222
- 12.4.5 AUSTRALIA 227
- 12.4.6 SINGAPORE 232
- 12.4.7 THAILAND 237
- 12.4.8 MALAYSIA 242
- 12.4.9 INDONESIA 247
- 12.4.10 PHILIPPINES 252
- 12.4.11 REST OF ASIA-PACIFIC 257
12.5 SOUTH AMERICA 258
- 12.5.1 BRAZIL 263
- 12.5.2 ARGENTINA 268
- 12.5.3 REST OF SOUTH AMERICA 273
12.6 MIDDLE EAST AND AFRICA 274
- 12.6.1 SOUTH AFRICA 279
- 12.6.2 SAUDI ARABIA 284
- 12.6.3 U.A.E 289
- 12.6.4 EGYPT 294
- 12.6.5 ISRAEL 299
- 12.6.6 REST OF MIDDLE EAST AND AFRICA 304

13 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE 305

13.1 COMPANY SHARE ANALYSIS: GLOBAL 305

14 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE 306

14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 306

15 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE 307

15.1 COMPANY SHARE ANALYSIS: EUROPE 307

16 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE 308

16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 308

17 SWOT ANALYSIS 309

18 COMPANY PROFILES 310

18.1 SAREPTA THERAPEUTICS, INC. 310
- 18.1.1 COMPANY SNAPSHOT 310
- 18.1.1 REVENUE ANALYSIS 311
- 18.1.2 COMPANY SHARE ANALYSIS 311
- 18.1.3 PRODUCT PORTFOLIO 312
- 18.1.4 PIPELINE PORTFOLIO 312
- 18.1.5 RECENT DEVELOPMENTS 312
18.2 F. HOFFMANN-LA ROCHE LTD 314
- 18.2.1 COMPANY SNAPSHOT 314
- 18.2.2 REVENUE ANALYSIS 314
- 18.2.3 COMPANY SHARE ANALYSIS 315
- 18.2.4 PRODUCT PORTFOLIO 315
- 18.2.5 PIPELINE PORTFOLIO 315
- 18.2.6 RECENT DEVELOPMENTS 315
18.3 PTC THERAPEUTICS. 316
- 18.3.1 COMPANY SNAPSHOT 316
- 18.3.2 REVENUE ANALYSIS 316
- 18.3.3 COMPANY SHARE ANALYSIS 317
- 18.3.4 PRODUCT PORTFOLIO 317
- 18.3.5 RECENT DEVELOPMENT 317
18.4 PFIZER INC. 318
- 18.4.1 COMPANY SNAPSHOT 318
- 18.4.2 REVENUE ANALYSIS 318
- 18.4.3 COMPANY SHARE ANALYSIS 319
- 18.4.4 PIPELINE PORTFOLIO 319
- 18.4.5 PRODUCT PORTFOLIO 319
- 18.4.6 RECENT DEVELOPMENT 319
18.5 AKASHI RX 320
- 18.5.1 COMPANY SNAPSHOT 320
- 18.5.2 PIPELINE PORTFOLIO 320
- 18.5.3 RECENT DEVELOPMENTS 320
18.6 AVIDITY BIOSCIENCES 321
- 18.6.1 COMPANY SNAPSHOT 321
- 18.6.2 REVENUE ANALYSIS 321
- 18.6.3 PIPELINE PORTFOLIO 322
- 18.6.4 RECENT DEVELOPMENTS 322
18.7 BIOMARIN 323
- 18.7.1 COMPANY SNAPSHOT 323
- 18.7.2 REVENUE ANALYSIS 323
- 18.7.3 PIPELINE PORTFOLIO 324
- 18.7.4 RECENT DEVELOPMENTS 324
18.8 CAPRICOR THERAPEUTICS, INC. 325
- 18.8.1 COMPANY SNAPSHOT 325
- 18.8.2 PIPELINE PORTFOLIO 325
- 18.8.3 RECENT DEVELOPMENTS 326
18.9 DYNE THERAPEUTICS 327
- 18.9.1 COMPANY SNAPSHOT 327
- 18.9.2 PIPELINE PORTFOLIO 327
- 18.9.3 RECENT DEVELOPMENTS 328
18.10 FIBROGEN, INC. 329
- 18.10.1 COMPANY SNAPSHOT 329
- 18.10.2 REVENUE ANALYSIS 329
- 18.10.3 PIPELINE PORTFOLIO 330
- 18.10.4 RECENT DEVELOPMENT 330
18.11 ITALFARMACO S.P.A. 331
- 18.11.1 COMPANY SNAPSHOT 331
- 18.11.2 PIPELINE PORTFOLIO 331
- 18.11.3 RECENT DEVELOPMENT 331
18.12 NS PHARMA, INC. 332
- 18.12.1 COMPANY SNAPSHOT 332
- 18.12.2 PIPELINE PORTFOLIO 332
- 18.12.3 RECENT DEVELOPMENTS 333
18.13 REVERAGEN BIOPHARMA, INC. 334
- 18.13.1 COMPANY SNAPSHOT 334
- 18.13.2 PIPELINE PORTFOLIO 334
- 18.13.3 RECENT DEVELOPMENT 334
18.14 SANTHERA PHARMACEUTICALS 335
- 18.14.1 COMPANY SNAPSHOT 335
- 18.14.2 REVENUE ANALYSIS 335
- 18.14.3 PIPELINE PORTFOLIO 336
- 18.14.4 RECENT DEVELOPMENT 336
18.15 TAIHO PHARMACEUTICAL CO., LTD. 337
- 18.15.1 COMPANY SNAPSHOT 337
- 18.15.2 PIPELINE PORTFOLIO 337
- 18.15.3 RECENT DEVELOPMENTS 337
18.16 SOLID BIOSCIENCES INC. 338
- 18.16.1 COMPANY SNAPSHOT 338
- 18.16.2 PIPELINE PORTFOLIO 338
- 18.16.3 RECENT DEVELOPMENT 338
18.17 STEALTH BIOTHERAPEUTICS INC 339
- 18.17.1 COMPANY SNAPSHOT 339
- 18.17.2 PIPELINE PORTFOLIO 339
- 18.17.3 RECENT DEVELOPMENT 339

19 QUESTIONNAIRE 340

20 RELATED REPORTS 343

LIST OF TABLES

TABLE 1 LIST OF PRICES FOR APPROVED DRUGS OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 66
TABLE 2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE , 2021-2030 (USD THOUSAND) 85
TABLE 3 GLOBAL MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 85
TABLE 4 GLOBAL MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 86
TABLE 5 GLOBAL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 86
TABLE 6 GLOBAL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 87
TABLE 7 GLOBAL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 8 GLOBAL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 88
TABLE 9 GLOBAL OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
TABLE 10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 93
TABLE 11 GLOBAL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 12 GLOBAL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 94
TABLE 13 GLOBAL MUTATION SUPPRESSION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 14 GLOBAL DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 96
TABLE 15 GLOBAL DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 96
TABLE 16 GLOBAL CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 97
TABLE 17 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2021-2030 (USD THOUSAND) 101
TABLE 18 GLOBAL PARENTERAL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 102
TABLE 19 GLOBAL ORAL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 103
TABLE 20 GLOBAL OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 104
TABLE 21 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USERS, 2021-2030 (USD THOUSAND) 108
TABLE 22 GLOBAL HOSPITALS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 109
TABLE 23 GLOBAL SPECIALITY CLINICS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 110
TABLE 24 GLOBAL HOMECARE IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 111
TABLE 25 GLOBAL OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 112
TABLE 26 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 117
TABLE 27 GLOBAL HOSPITAL PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 117
TABLE 28 GLOBAL RETAIL PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 118
TABLE 29 GLOBAL ONLINE PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 119
TABLE 30 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 123
TABLE 31 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) COUNTRY 124
TABLE 32 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 33 NORTH AMERICA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 34 NORTH AMERICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 35 NORTH AMERICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 125
TABLE 36 NORTH AMERICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 37 NORTH AMERICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 125
TABLE 38 NORTH AMERICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 39 NORTH AMERICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 126
TABLE 40 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 126
TABLE 41 NORTH AMERICA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 126
TABLE 42 NORTH AMERICA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 127
TABLE 43 NORTH AMERICA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 127
TABLE 44 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 127
TABLE 45 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 128
TABLE 46 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 128
TABLE 47 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 48 U.S. MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 49 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 50 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 130
TABLE 51 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 130
TABLE 52 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 53 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 130
TABLE 54 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 131
TABLE 55 U.S. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 56 U.S. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 131
TABLE 57 U.S. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 131
TABLE 58 U.S.DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 132
TABLE 59 U.S. EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 132
TABLE 60 U.S. DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 132
TABLE 61 U.S. CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 132
TABLE 62 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 133
TABLE 63 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 133
TABLE 64 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
TABLE 65 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 66 CANADA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 67 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 68 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 135
TABLE 69 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 135
TABLE 70 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 71 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 135
TABLE 72 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 136
TABLE 73 CANADA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 74 CANADA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 136
TABLE 75 CANADA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 136
TABLE 76 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 137
TABLE 77 CANADA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 137
TABLE 78 CANADA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 137
TABLE 79 CANADA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 137
TABLE 80 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 138
TABLE 81 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 138
TABLE 82 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 138
TABLE 83 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 84 MEXICO MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 85 MEXICO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 86 MEXICO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 140
TABLE 87 MEXICO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 140
TABLE 88 MEXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 89 MEXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 140
TABLE 90 MEXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 141
TABLE 91 MEXICO STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 92 MEXICO STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 141
TABLE 93 MEXICO STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 141
TABLE 94 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 142
TABLE 95 MEXICO EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 142
TABLE 96 MEXICO DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 142
TABLE 97 MEXICO CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 143
TABLE 98 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 143
TABLE 99 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 143
TABLE 100 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 144
TABLE 101 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 145
TABLE 102 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 103 EUROPE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 104 EUROPE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 105 EUROPE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 147
TABLE 106 EUROPE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 107 EUROPE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 147
TABLE 108 EUROPE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 109 EUROPE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 148
TABLE 110 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 148
TABLE 111 EUROPE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 148
TABLE 112 EUROPE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 149
TABLE 113 EUROPE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 149
TABLE 114 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 149
TABLE 115 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 150
TABLE 116 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 150
TABLE 117 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 118 GERMANY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 119 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 120 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 152
TABLE 121 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 152
TABLE 122 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 152
TABLE 123 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 152
TABLE 124 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 153
TABLE 125 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 153
TABLE 126 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 153
TABLE 127 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 153
TABLE 128 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
TABLE 129 GERMANY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
TABLE 130 GERMANY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
TABLE 131 GERMANY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
TABLE 132 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 155
TABLE 133 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 155
TABLE 134 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 155
TABLE 135 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 156
TABLE 136 FRANCE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 156
TABLE 137 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 156
TABLE 138 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 157
TABLE 139 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 157
TABLE 140 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 157
TABLE 141 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 157
TABLE 142 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 158
TABLE 143 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 144 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 158
TABLE 145 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 158
TABLE 146 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 159
TABLE 147 FRANCE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 159
TABLE 148 FRANCE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 159
TABLE 149 FRANCE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 159
TABLE 150 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 160
TABLE 151 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 160
TABLE 152 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 160
TABLE 153 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 161
TABLE 154 U.K. MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 161
TABLE 155 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 161
TABLE 156 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 162
TABLE 157 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 162
TABLE 158 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 162
TABLE 159 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 162
TABLE 160 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 163
TABLE 161 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 163
TABLE 162 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 163
TABLE 163 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 163
TABLE 164 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 164
TABLE 165 U.K. EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 164
TABLE 166 U.K. DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 164
TABLE 167 U.K. CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 164
TABLE 168 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 165
TABLE 169 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 165
TABLE 170 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 165
TABLE 171 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 166
TABLE 172 ITALY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 166
TABLE 173 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 166
TABLE 174 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 167
TABLE 175 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 167
TABLE 176 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 167
TABLE 177 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 167
TABLE 178 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 168
TABLE 179 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 168
TABLE 180 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 168
TABLE 181 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 168
TABLE 182 ITALYDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 169
TABLE 183 ITALY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 169
TABLE 184 ITALY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 169
TABLE 185 ITALY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 169
TABLE 186 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 170
TABLE 187 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 170
TABLE 188 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 170
TABLE 189 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 171
TABLE 190 SPAIN MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 171
TABLE 191 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 171
TABLE 192 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 172
TABLE 193 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 172
TABLE 194 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 172
TABLE 195 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 172
TABLE 196 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 173
TABLE 197 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 173
TABLE 198 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 173
TABLE 199 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 173
TABLE 200 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 174
TABLE 201 SPAIN EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 174
TABLE 202 SPAIN DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 174
TABLE 203 SPAIN CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 174
TABLE 204 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 175
TABLE 205 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 175
TABLE 206 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 175
TABLE 207 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
TABLE 208 RUSSIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
TABLE 209 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
TABLE 210 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 177
TABLE 211 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 177
TABLE 212 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 177
TABLE 213 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 177
TABLE 214 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 178
TABLE 215 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 178
TABLE 216 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 178
TABLE 217 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 178
TABLE 218 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 179
TABLE 219 RUSSIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 179

TABLE 220 RUSSIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 179
TABLE 221 RUSSIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 179
TABLE 222 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 180
TABLE 223 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 180
TABLE 224 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 180
TABLE 225 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 181
TABLE 226 TURKEY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 181
TABLE 227 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 181
TABLE 228 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 182
TABLE 229 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 182
TABLE 230 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 182
TABLE 231 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 182
TABLE 232 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 183
TABLE 233 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 183
TABLE 234 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 183
TABLE 235 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 183
TABLE 236 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 184
TABLE 237 TURKEY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 184
TABLE 238 TURKEY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 184
TABLE 239 TURKEY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 184
TABLE 240 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 185
TABLE 241 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 185
TABLE 242 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 185
TABLE 243 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 186
TABLE 244 BELGIUM MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 186
TABLE 245 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 186
TABLE 246 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 187
TABLE 247 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 187
TABLE 248 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 187
TABLE 249 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 187
TABLE 250 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 188
TABLE 251 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 188
TABLE 252 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 188
TABLE 253 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 188
TABLE 254 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 189
TABLE 255 BELGIUM EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 189
TABLE 256 BELGIUM DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 189
TABLE 257 BELGIUM CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 189
TABLE 258 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 190
TABLE 259 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 190
TABLE 260 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 190
TABLE 261 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 191
TABLE 262 NETHERLANDS MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 191
TABLE 263 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 191
TABLE 264 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 192
TABLE 265 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 192
TABLE 266 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 192
TABLE 267 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 192
TABLE 268 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 193
TABLE 269 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 193
TABLE 270 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 193
TABLE 271 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 193
TABLE 272 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 194
TABLE 273 NETHERLANDS EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 194
TABLE 274 NETHERLANDS DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 194
TABLE 275 NETHERLANDS CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 194
TABLE 276 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 195
TABLE 277 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 195
TABLE 278 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 195
TABLE 279 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 196
TABLE 280 SWITZERLAND MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 196
TABLE 281 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 196
TABLE 282 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 197
TABLE 283 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 197
TABLE 284 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 197
TABLE 285 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 197
TABLE 286 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 198
TABLE 287 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 198
TABLE 288 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 198
TABLE 289 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 198
TABLE 290 SWITZERLANDDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 199
TABLE 291 SWITZERLAND EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 199
TABLE 292 SWITZERLAND DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 199
TABLE 293 SWITZERLAND CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 199
TABLE 294 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 200
TABLE 295 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 200
TABLE 296 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 200
TABLE 297 REST OF EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 201
TABLE 298 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 202
TABLE 299 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 202
TABLE 300 ASIA-PACIFIC MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 203
TABLE 301 ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 203
TABLE 302 ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 203
TABLE 303 ASIA-PACIFIC NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 204
TABLE 304 ASIA-PACIFIC NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 204
TABLE 305 ASIA-PACIFIC STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 204
TABLE 306 ASIA-PACIFIC STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 204
TABLE 307 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 205
TABLE 308 ASIA-PACIFIC EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 205
TABLE 309 ASIA-PACIFIC DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 205
TABLE 310 ASIA-PACIFIC CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 205
TABLE 311 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 206
TABLE 312 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 206
TABLE 313 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 206
TABLE 314 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 207
TABLE 315 CHINA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 207
TABLE 316 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 207
TABLE 317 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 208
TABLE 318 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 208
TABLE 319 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 208
TABLE 320 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 208
TABLE 321 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 209
TABLE 322 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 209
TABLE 323 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 209
TABLE 324 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 209
TABLE 325 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 210
TABLE 326 CHINA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 210
TABLE 327 CHINA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 210
TABLE 328 CHINA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 210
TABLE 329 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 211
TABLE 330 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 211
TABLE 331 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 211
TABLE 332 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 212
TABLE 333 JAPAN MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 212
TABLE 334 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 212
TABLE 335 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 213
TABLE 336 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 213
TABLE 337 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 213
TABLE 338 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 213
TABLE 339 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 214
TABLE 340 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 214
TABLE 341 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 214
TABLE 342 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 214
TABLE 343 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 215
TABLE 344 JAPAN EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 215
TABLE 345 JAPAN DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 215
TABLE 346 JAPAN CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 215
TABLE 347 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 216
TABLE 348 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 216
TABLE 349 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 216
TABLE 350 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 217
TABLE 351 INDIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 217
TABLE 352 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 217
TABLE 353 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 218
TABLE 354 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 218
TABLE 355 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 218
TABLE 356 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 218
TABLE 357 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 219
TABLE 358 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 219
TABLE 359 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 219
TABLE 360 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 219
TABLE 361 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 220
TABLE 362 INDIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 220
TABLE 363 INDIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 220
TABLE 364 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 221
TABLE 365 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 221
TABLE 366 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 221
TABLE 367 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 222
TABLE 368 SOUTH KOREA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 222
TABLE 369 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 222
TABLE 370 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 223
TABLE 371 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 223
TABLE 372 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 223
TABLE 373 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 223
TABLE 374 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 224
TABLE 375 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 224
TABLE 376 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 224
TABLE 377 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 224
TABLE 378 SOUTH KOREADUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 225
TABLE 379 SOUTH KOREA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 225
TABLE 380 SOUTH KOREA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 225
TABLE 381 SOUTH KOREA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 225
TABLE 382 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 226
TABLE 383 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 226
TABLE 384 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 226
TABLE 385 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 227
TABLE 386 AUSTRALIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 227
TABLE 387 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 227
TABLE 388 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 228
TABLE 389 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 228
TABLE 390 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 228
TABLE 391 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 228
TABLE 392 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 229
TABLE 393 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 229
TABLE 394 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 229
TABLE 395 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 229
TABLE 396 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 230
TABLE 397 AUSTRALIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 230
TABLE 398 AUSTRALIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 230
TABLE 399 AUSTRALIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 230
TABLE 400 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 231
TABLE 401 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 231
TABLE 402 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 231
TABLE 403 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 232
TABLE 404 SINGAPORE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 232
TABLE 405 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 232
TABLE 406 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 233
TABLE 407 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 233
TABLE 408 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 233
TABLE 409 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 233
TABLE 410 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 234
TABLE 411 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 234
TABLE 412 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 234
TABLE 413 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 234
TABLE 414 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 235
TABLE 415 SINGAPORE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 235
TABLE 416 SINGAPORE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 235
TABLE 417 SINGAPORE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 235
TABLE 418 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 236
TABLE 419 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 236
TABLE 420 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 236
TABLE 421 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 237
TABLE 422 THAILAND MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 237
TABLE 423 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 237
TABLE 424 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 238
TABLE 425 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 238
TABLE 426 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 238
TABLE 427 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 238
TABLE 428 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 239
TABLE 429 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 239
TABLE 430 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 239
TABLE 431 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 239
TABLE 432 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 240
TABLE 433 THAILAND EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 240
TABLE 434 THAILAND DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 240
TABLE 435 THAILAND CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 240
TABLE 436 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 241
TABLE 437 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 241
TABLE 438 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 241
TABLE 439 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 242
TABLE 440 MALAYSIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 242
TABLE 441 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 242
TABLE 442 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 243
TABLE 443 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 243
TABLE 444 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 243
TABLE 445 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 243
TABLE 446 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 244
TABLE 447 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 244
TABLE 448 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 244
TABLE 449 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 244
TABLE 450 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 245
TABLE 451 MALAYSIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 245
TABLE 452 MALAYSIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 245
TABLE 453 MALAYSIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 245
TABLE 454 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 246
TABLE 455 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 246
TABLE 456 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 246
TABLE 457 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 247
TABLE 458 INDONESIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 247
TABLE 459 INDONESIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 247

LIST OF FIGURES

FIGURE 1 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: SEGMENTATION 49
FIGURE 2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DATA TRIANGULATION 52
FIGURE 3 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DROC ANALYSIS 53
FIGURE 4 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 54
FIGURE 5 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 54
FIGURE 6 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 55
FIGURE 7 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: MARKET END USER COVERAGE GRID 57
FIGURE 8 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DBMR MARKET POSITION GRID 58
FIGURE 9 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: VENDOR SHARE ANALYSIS 59
FIGURE 10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: SEGMENTATION 62
FIGURE 11 THE RISING PREVALENCE AND IMPACT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) AND INTRODUCTION OF NOVEL THERAPIES FOR DMD DISORDER ARE EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET FROM 2023 TO 2030 63
FIGURE 12 MOLECULAR-BASED THERAPIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET IN 2023 AND 2030 63
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 71
FIGURE 14 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE , 2022 82
FIGURE 15 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 83
FIGURE 16 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE , CAGR (2023-2030) 83
FIGURE 17 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE 84
FIGURE 18 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, 2022 91
FIGURE 19 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, 2023-2030 (USD THOUSAND) 92
FIGURE 20 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, CAGR (2023-2030) 92
FIGURE 21 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, LIFELINE CURVE 93
FIGURE 22 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 99
FIGURE 23 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 100
FIGURE 24 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 100
FIGURE 25 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 101
FIGURE 26 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, 2022 106
FIGURE 27 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 107
FIGURE 28 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, CAGR (2023-2030) 107
FIGURE 29 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, LIFELINE CURVE 108
FIGURE 30 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 114
FIGURE 31 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 115
FIGURE 32 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 115
FIGURE 33 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 116
FIGURE 34 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET SNAPSHOT 122
FIGURE 35 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%) 305
FIGURE 36 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%) 306
FIGURE 37 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%) 307
FIGURE 38 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%) 308